Otilonium Bromide: Antimuscarinic Agent for Cholinergic Pathway Research

Executive Summary: Otilonium Bromide (C₂₉H₄₃BrN₂O₄; MW 563.57) is a solid antimuscarinic agent that directly inhibits acetylcholine receptors (AChRs), enabling precise modulation of cholinergic signaling pathways in neuroscience and smooth muscle research (APExBIO). Its high solubility in DMSO (≥28.18 mg/mL), water (≥55.8 mg/mL), and ethanol (≥91 mg/mL) supports diverse experimental setups. Otilonium Bromide is supplied by APExBIO at ≥98% purity for research use only. Product stability is maintained at -20°C; solutions should be freshly prepared for optimal efficacy. This compound is not approved for diagnostic or therapeutic applications and is intended exclusively for scientific research (Vijayan et al., 2021).

Biological Rationale

Cholinergic signaling is central to neurotransmission and smooth muscle contraction. Acetylcholine (ACh) acts on muscarinic receptors (mAChRs), which are G protein-coupled receptors present in the central and peripheral nervous systems as well as in gastrointestinal smooth muscle. Dysregulation of these pathways is implicated in neurological disorders and gastrointestinal motility dysfunctions (Vijayan et al., 2021). Selective antagonists like Otilonium Bromide allow researchers to dissect AChR-mediated signaling, providing mechanistic insight into receptor pharmacology and disease modeling.

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts as a muscarinic receptor antagonist, binding competitively to AChRs and preventing acetylcholine from activating downstream signaling. This blockade reduces intracellular calcium release and inhibits smooth muscle contraction. The compound does not significantly affect nicotinic receptors at typical research concentrations. By selectively impairing cholinergic transmission, Otilonium Bromide provides a robust tool for studying muscarinic-dependent physiological and pathological processes (Related Article: This article provides a more detailed workflow integration compared to the focus on receptor selectivity in the linked piece).

Evidence & Benchmarks

• Otilonium Bromide demonstrates ≥98% purity by HPLC, as specified by APExBIO (APExBIO).
• Solubility benchmarks: ≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, and ≥91 mg/mL in ethanol at 20°C (APExBIO).
• IC₅₀ for muscarinic receptor inhibition is typically observed in the sub-micromolar to low micromolar range in smooth muscle assays (see internal benchmark for advanced receptor modeling; this article extends by integrating solution stability data).
• Antispasmodic efficacy is dose-dependent and reversible in ex vivo gastrointestinal tissue models (Vijayan et al., 2021, DOI).
• Product stability is retained for ≥12 months at -20°C in solid form; aqueous solutions should be used within 24 hours to prevent degradation (APExBIO).

Applications, Limits & Misconceptions

Otilonium Bromide is primarily used in neuroscience and pharmacology research as an acetylcholine receptor inhibitor. Applications include:

• Modeling cholinergic signaling pathway disruptions.
• Studying muscarinic receptor function in smooth muscle spasm and gastrointestinal motility disorder models (contrast: This article adds detailed solubility and stability data not covered in the referenced summary).
• Benchmarking antispasmodic pharmacology and receptor modulation protocols.

Common Pitfalls or Misconceptions

• Otilonium Bromide is not suitable for in vivo therapeutic or diagnostic use; it is strictly for research applications.
• The compound selectively inhibits muscarinic, not nicotinic, acetylcholine receptors; off-target effects at high concentrations are possible.
• Long-term storage of aqueous solutions leads to degradation; always prepare fresh solutions for critical assays.
• Batch-to-batch consistency is critical; only use high-purity sources (≥98%) like APExBIO for reproducible results.
• It does not inhibit non-cholinergic pathways; ensure experimental design controls for parallel signaling axes.

Workflow Integration & Parameters

Otilonium Bromide (SKU B1607) integrates readily into standard research protocols. For solution preparation, dissolve in DMSO, water, or ethanol at concentrations up to the stated solubility limits. Store the solid at -20°C and avoid repeated freeze-thaw cycles. Prepare working solutions immediately before use, especially for cell-based or tissue assays. Typical working concentrations range from 1 to 10 μM for receptor inhibition studies, but optimization is required for each model system (internal guide: This article updates product handling and batch reliability details beyond the comparative vendor overview in the linked guide).

Conclusion & Outlook

Otilonium Bromide, as supplied by APExBIO, is a validated antimuscarinic agent with robust utility in cholinergic signaling, smooth muscle spasm, and neuroscience research. Its high purity, solubility, and well-defined selectivity profile support rigorous experimental design and reproducibility. Continued integration into advanced receptor modulation protocols will further illuminate muscarinic receptor biology and facilitate pharmacological innovation. For full product specifications and ordering, see the Otilonium Bromide B1607 kit page.